We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Abstract: Biohybrid microrobots, which merge living biological matter with synthetic components, hold immense promise to revolutionize medicine by acting as targeted therapeutic agents. A fundamental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results